Twenty years ago, Roger Cone, Ph.D. made a key discovery in obesity science which could help Courage Therapeutics deliver ...

Life sciences companies can look to the automotive industry for ideas about collaborating with patients to co-create new ...

By sharing early-stage tools and data openly, life sciences companies can minimize duplication and de-risk R&D without ...

Crystalline forms of compounds and salts are frequently claimed in chemical patents, including in pharmaceuticals and agrochemicals. Different crystalline forms of the same substance — that is, ...

Driving growth in a family-owned pharma company requires a balance of progress and preservation, writes Merz Therapeutics CEO Stefan König.

Fear of change is a key limiting factor that is slowing the adoption and value of AI across life sciences. It doesnt have to be that way, writes Anastasia Christianson, Ph.D.

Cuts to federal research funding at universities and research organizations are pushing academic scientists into life sciences entrepreneurship. Experts at Sidley offer tips for the transition.

Proper legal structuring is essential when it comes to transferring Chinese biotech intellectual property and clinical assets to form a U.S.-based Newco, explain experts at Orrick.

After decades of racing to the bottom on pricing, a revolution is coming to the U.S. generics market, writes Yaral Pharma CEO Stephen Beckman.

Experts at Faegre Drinker offer life sciences business planning and risk mitigation strategies to consider in response to enacted or anticipated policy changes under the Trump administration.

Modern drug development approaches that integrate functional plans with larger business goals are needed for success in early and late-stage drug development, explains Hallorans Carolina Ahrendt.

For small pharmas and biotechs approaching a commercial launch, agility and execution are more valuable than waiting for a perfect plan, writes Melinta Therapeutics CEO John Harlow.